miRNAs as Essential Mediators of the Actions of Retinoic Acid in Neuroblastoma Cells by Meseguer, Salvador et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 11
miRNAs as Essential Mediators of the Actions of Retinoic
Acid in Neuroblastoma Cells
Salvador Meseguer, Juan-Manuel Escamilla and
Domingo Barettino
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/55444
1. Introduction
The discovery of microRNAs (miRNAs, miRs) led to a profound change on our vision about the
regulation of gene expression in eukaryotes. MicroRNAs are an emerging class of small non-
coding endogenous RNAs that participate on the fine tuning of gene expression at the post-
transcriptional level. First discovered at the early 90s in the nematode C. elegans [1], microRNAs
have been involved in multiple important biological processes both in animal as in plant cells.
These regulatory RNAs are transcribed as primary longer transcripts, which are then processed
into 19-23-nt mature miRNAs. One strand of the mature miRNA is then incorporated into the
RNA-induced silencing complex (RISC) to regulate gene expression by targeting the 3’-untrans‐
lated region (3’UTR) of mRNAs with consequent translational repression and/or target mRNA
degradation. This mode of action demonstrates the great regulatory potential of miRNAs, since
a unique mRNA can be targeted by diverse miRNAs and conversely each miRNA may have
hundreds of different target mRNAs. In recent years miRNAs have been established as impor‐
tant regulators of tumor development, progression and metastasis, and have demonstrated to be
useful for tumor diagnosis and classification. Moreover, miRNA regulation might represent a
new avenue for cancer treatment in a near future.
Neuroblastoma is the most common extracranial solid tumor in childhood and the most
common tumor in infants, which originates from aberrant development of primordial neural
crest cells. Several lines of evidence support the idea that microRNA deregulation could
contribute to neuroblastoma pathogenesis and progression [2, 3], and the usefulness of miRNA
profiles for neuroblastoma diagnostics, classification and prognosis has been recently reported
[4]. Neuroblastoma cell lines can be induced to differentiate in vitro by several agents, including
Retinoic Acid (RA) [5, 6], the biologically active form of vitamin A. RA treatments lead to
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proliferative arrest and neuronal differentiation [5, 7] and to a reduction of the biological
aggressiveness of neuroblastoma cells, by reducing their migratory and invasive abilities
[8-10]. As a consequence of this, RA and its derivatives have been introduced into therapeutic
protocols for neuroblastoma patients [11-13].
In this article we want to review the evidences supporting the contribution of miRNA
regulation to RA-induced differentiation of neuroblastoma cells. We will show that miRNA
contribute to the gene-expression changes associated with neuroblastoma cell differentiation
and that specific RA-induced miRNAs target the expression of relevant genes in the context
of neural differentiation. In addition RA-regulated miRNAs contribute to the reduction in the
biological aggressiveness elicited by RA in vitro. We put forward the idea that miRNA
regulation is part of the RA signaling pathway, and that miRNAs are essential mediators of
the actions of RA in neuroblastoma cells.
2. The molecular bases of miRNA action
2.1. Biogenesis of miRNAs
miRNAs use complementary base pairing and the RNA induced silencing complex (RISC) to
bind and either block translation and/or promote degradation of their target mRNAs. miRNAs
are 19-22 nt-long RNA molecules transcribed mainly from non-coding regions of the genome,
although some are embedded within genes, primarily as part of intronic sequences [14]. In
addition, clusters of miRNAs were also found in the genome [15]. miRNAs are transcribed as
large hairpin-containing molecules, called pri-miRNA, that are cleaved in the nucleus by the
microprocessor complex, involving Drosha and Pasha/DGCR8 proteins [16, 17]. The result of
this cleavage is a shorter precursor hairpin (approx. 70 nt), called pre-miRNA. Pre-miRNAs
are exported through RAN GTPase and exportin-5 to the cytoplasm [18] where undergo further
cleavage by Dicer to yield a transient intermediate imperfect duplex of approx 19-22 bp miRNA
[19]. Subsequently, the duplex unwinds and miRNA strand is loaded into RISC complex
together with proteins of the Argonaute (Ago) family [20]. The miRNA strand in RISC acts as
a guide strand to find the complementary site in mRNA, and thereby suppressing the
translational activity of the target mRNA. The complementary strand (known as miRNA* or
as passenger strand) is degraded when the duplex is unwound, although recent evidences
show that in some cases miRNA* accumulated at physiological levels and support the idea of
a role for miRNA* on gene regulation [21]. (see Figure 1)
2.2. miRNA target binding
miRNAs interact primarily with the 3’-untranslated (3’UTR) region of their target mRNAs,
although recent evidences show that miRNAs can also associate with sites located within the
coding region of target genes [22]. In fact, complex arrays of multiple binding sites for either
the same or different miRNAs located both in the 3’UTR as well as in the coding region of the
target genes have been reported [23]. The base pairing of miRNA and mRNA in vertebrates
requires only partial homology, with a preference for contiguous pairing occurring only at the
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seed region, located at nucleotides 2-7 of the guide strand. The lack of stringency results in a
many-to-many relationship between miRNAs and mRNA targets, with the consequence that
a high percentage of the genome may be regulated post-transcriptionally by a comparatively
small set of miRNAs. A consequence of that is also that bioinformatic prediction of miRNA
target mRNAs becomes relatively inaccurate. The guide strand binds to its complementary
region in the 3′UTR of its target mRNA through Watson–Crick base pairing of the seed
residues. Several alternative seed binding arrangements have been observed that involved
different number of residues and therefore could have different binding affinity [24].
Figure 1. miRNA Biogenesis. The scheme depicts the different steps in the biogenesis of miRNAs, the enzymes in‐
volved and the intermediate miRNA forms.
2.3. Suppression of mRNA translation and/or mRNA degradation mediated by miRNAs
The binding of miRNA-RISC complex to its cognate mRNA target leads to mRNA silencing
through suppression of mRNA translation and/or mRNA decay. [25, for review] Several
mechanisms involving different protein complexes have been proposed. mRNA translation
could be blocked at initiation step as well as post-initiation stages. The miRNA-RISC complex
inhibits translation initiation by interfering with eIF4F-cap recognition and 40S small riboso‐
mal subunit recruitment or by antagonizing 60S subunit joining and preventing 80S ribosomal
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complex formation. The interaction of the GW182 protein with the poly(A)-binding protein
(PABP) might interfere with the closed-loop formation mediated by the eIF4G-PABP interac‐
tion and thus contribute to the repression of translation initiation. The miRNA-RISC might
inhibit also translation at post-initiation steps by inhibiting ribosome elongation, inducing
ribosome drop-off, or promoting proteolysis of nascent polypeptides. To promote mRNA
degradation, the miRNA-RISC complex interacts with the CCR4-NOT1 deadenylase complex
to facilitate deadenylation of the mRNA poly(A) tail. Deadenylation requires the direct
interaction of the GW182 protein with PABP. Following deadenylation, the 5′-terminal cap
(m7G) is removed by the DCP1-DCP2 decapping complex. Although miRNA-mediated
deadenylation followed by mRNA degradation appear to be widespread events, not all
miRNA-targeted mRNAs are destabilized. miRNA-targeted translationally repressed mRNAs
can accumulate in discrete cytoplasmic foci, such as P or GW bodies, or stress granules. A
fraction of GW bodies co-localizes with multivesicular bodies (MVBs), membrane structures
that play a role in miRNA-mediated repression. Compelling evidences support a role for
miRNAs at the nucleus, acting on transcriptional regulation via chromatin remodeling and
epigenetic mechanisms [26].
3. Profiling miRNA expression during retinoic-acid-induced
neuroblastoma cell differentiation
3.1. Profiling miRNA expression during retinoic-acid induced neuroblastoma cell
differentiation
Several studies have addressed the changes in the expression of miRNAs upon RA-dependent
induction of differentiation of neuroblastoma cells, with somewhat different results depending
on the cell line, treatment duration, analysis platform used, etc. [2, 27-30]. To analyze the
contribution of microRNA regulation to RA-induced differentiation of neuroblastoma cells,
we have studied the changes in the pattern of expression of 667 different human miRNAs upon
RA treatment of SH-SY5Y neuroblastoma cells. We used miRNA profiling with TaqMan RT-
PCR Low Density Arrays, and we found that 452 miRNAs were expressed above detection
level. From them, 42 specific miRNAs change significatively their expression levels (26
upregulated and 16 downregulated) during RA-induced differentiation (Figure 2). This
suggests miRNAs as an additional post-transcriptional regulatory layer under RA control [30].
3.2. A role for miRNAs-10a and -10b in RA-dependent regulation of neuroblastoma
differentiation
We have focused our study on the closely related miR-10a and -10b, that showed the most
prominent expression changes in SH-SY5Y cell line. Similar results have been reported for
other neuroblastoma cell lines, like LA-N-1, LAN5 and SK-N-BE [29, 30].
Loss of function experiments with anti-sense anti-miRs antagonists could show that miR-10a
and -10b contribute to the regulation of RA-induced differentiation. RA-induced neurite
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outgrowth was impaired in cells with experimentally reduced levels of miR-10a or -10b, and
the expression of several neural differentiation markers like Tyrosine Kinase receptors NTRK2
Figure 2. miRNA expression profiling in differentiating SH-SY5Y cells. Relative expression values detected in Taq‐
Man microRNA Low Density Arrays for microRNAs with FDR<0.05 at least in two of the three treated versus non-treat‐
ed comparisons, for upregulated (A) and downregulated miRNAs (B). The values for 24 (empty bars), 48 (grey bars)
and 96 (black bars) h of RA treatment are represented.
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(trkB) and RET, GAP43, Neuron-specific Enolase (ENO2), medium-size neurofilament protein
NEFM and the enzyme Tyrosine Hydroxylase (TH) was abrogated or severely impaired after
suppression of miR-10a or -10b (Figure 3).
Figure 3. Knock-down of miR-10a and -10b impaired RA-induced differentiation. Blocking the action of miR-10a
and -10b by transfection of their cognate anti-miRs diminished neurite outgrowth (A) and reduced the expression of
neuronal differentiation markers NTRK2 (B), RET (C), GAP43 (D) and ENO2 (E), as shown by quantitative RT-PCR. (Statis‐
tical signification in the Figures: *: p<0.05; **: p<0.01; ***: p<0,001; ns: non significative)
Conversely, the downregulation of the members of the ID gene family, ID1, ID2 and ID3 was
abolished in RA-treated cells transfected with anti-miR-10a and anti-miR-10b. However,
miR-10a and -10b did not appear to play a relevant role in RA-induced proliferation arrest,
because the strong reduction of the incorporation of 3H-Thymidine (to approximately 30% of
the control values) and the decrease in the percentage of cells in S- phase (to 50% of the control)
induced by RA treatment, was equivalent in neuroblastoma cells transfected with anti-miR-10a
and anti-miR-10b [30]. However, a reduction in the cell growth in SK-N-BE neuroblastoma
cells when transfected with pre-miR-10a and -10b has been reported [29]. Overexpression of
miR-10 and -10b by transfecting synthetic precursor pre-miRs could not trigger full differen‐
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tiation itself and although the mRNA levels of RET, NTRK2, GAP43 and ENO2 or the protein
levels of NEFM and TH were slightly enhanced by transfection of pre-miR-10a and -10b, the
attained expression levels for all the markers analyzed were far below those obtained by RA
treatment. Similarly, ectopic expression of miR-10a and -10b led to certain increase in neurite
outgrowth, but lower to that obtained for RA treatment [30]. Therefore, miR-10a and-10b
appeared to be necessary but not sufficient for full neural differentiation, and consequently
additional actions of RA must contribute to differentiation.
3.3. miRNAs-10a and -10b contribute to the reduction on the biological aggressiveness of
neuroblastoma cells induced by RA
It has been reported that RA treatment of neuroblastoma cells results in a reduction in their
biological aggressiveness, by decreasing their migratory and invasive abilities [8-10]. We
wanted to analyze whether RA-induced expression of miR-10a and -10b could be related to
the reduction in migratory and invasive potential of neuroblastoma cells. To test the migratory
potential of SH-SY-5Y cells we used a modified, light-opaque Boyden chamber assay (Falcon
HTS FluoroBlok, 8 μm pore size). Cells were transfected with anti-miR-10a or -10b or the
corresponding Negative Control anti-miR, treated with 1 μM RA or vehicle in culture medium
during 96 h, and labeled in the plate with Calcein AM. Labeled cells were counted and added
to the upper chamber of the Boyden chamber, and allow to migrate towards de lower chamber,
filled with medium containing 10% FBS as chemoattractant. The results show that indeed RA-
treatment reduced the migration of neuroblastoma cells. However suppressing miR-10a or
-10b expression not only abolished that reduction but increased migration over basal levels,
supporting a contribution of RA-induced miR-10a and 10b to the reduction of migratory
activity produced by RA [30]. (Figure 4A)
Figure 4. Involvement of miR-10a and -10b on the effects of RA in migratory and invasive potential of neuro‐
blastoma cells. Mock-transfected cells and cells transfected with Negative Control (NC) anti-miR, anti-miR-10a or anti-
miR-10b were treated with 1 μM RA or vehicle for 96 h and used in migration (A) or matrigel invasion (B) transwell
assays. The graph shows a representative experiment performed in triplicate (mean ± SD). Statistical significance was
analyzed by comparing samples transfected with anti-miR-10a and -10b with those transfected with NC-anti-miR.
For invasion assays we used a similar assay, with the difference that the porous membrane
separating the upper and lower chambers of the Boyden chamber was covered with BD Matrigel
matrix (5 μg/cm2 in serum-free medium). The lower chamber contained 10% FBS as chemoattrac‐
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tant to promote cell invasion. In this case RA treatment results in increased invasive potential,
whereas in cells transfected with anti-miR-10a or 10b the same treatment the increase in inva‐
sion induced by RA treatment is even larger, supporting the idea that the expression of miR-10a
and -10b contributes to a reduction in the invasive potential [30]. (Figure 4B)
To analyze the effects of RA treatment on the metastatic potential of neuroblastoma cells we
used the chicken embryo chorioallantoic membrane assays (also known as CAM assay; [31]).
This assay is useful to study intravasation and metastasis in vivo, since it recapitulates all the
steps of the metastatic process. In the CAM assay the cells to be tested are inoculated on the
chorioallantoic membrane of 10-day-old chicken embryos. After a week, the egg is opened, the
embryo is obtained and secondary organs like the lungs were dissected. The presence of human
cells in the chicken organ is evaluated and quantified after obtaining their genomic DNA, by
detecting the presence of human-specific Alu-sequences by Real-Time PCR (Figure 3). As this
is a complex technique that requires a higher number of replicate experiments we have
simplified the study to analyze only the effects of miR-10a suppression. Neuroblastoma cells
could be detected in the chicken lungs after 7 days incubation. Suppression of miR-10a
expression with its cognate anti-miR resulted in an increase of the metastatic cells. As expected,
RA treatment led to a reduction of the number of neuroblastoma cells reaching the lungs.
However this inhibitory effect of RA was abolished in cells having a reduced amount of
miR-10a by transfecting the corresponding anti-miR-10a [30].
In good agreement with our results, it has been reported that miR-10a and -10b reduces the
ability of neuroblastoma cells to form colonies in soft agar [29], a phenotype that is character‐
istic of malignant cells. All these results support the idea that miR-10a and -10b expression
contribute to reduction of migratory, invasive and metastatic activities induced by RA. In a
recent report it has been shown that a protein involved in cell migration, Tiam1, is targeted by
miR-10b in mammary tumor cells. Overexpression of miR-10b suppresses the ability of breast
carcinoma cells to migrate and invade [32]. Consistent to that, it has been reported an associ‐
ation between lower miR-10a expression and lower overall survival for a subclass of neuro‐
blastoma tumors (11q- tumor cohort) [29]. However other reports seem to involve the members
of the miR-10 family as promoters of migration and metastasis in different tumors [33-40]. This
apparent controversy may suggest that the role of the microRNAs from the miR-10 family in
tumorigenesis and metastasis would depend on their molecular targets and therefore would
depend on the cellular context.
4. Molecular targets of miR-10a and -10b in the differentiation of
neuroblastoma cells
4.1. The search for the molecular targets for miRNAs
The identification of molecular targets for miRNAs is a crucial step towards the understanding
of miRNA function. Because an ever growing number of experimentally validated targets for
miRNAs are being reported, a simple way to identify miRNA targets is to search for validated
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targets in the literature or in databases as TarBase [41]. A validated target for miR-10b in breast
cancer cells is the homeobox gene HOXD10 [34, 42]. However, we could not find regulation of
HOXD10 in SH-SY5Y neuroblastoma cells, when treated with RA or when the levels of miR-10a
and -10b were experimentally altered [30].
A lot of effort has been made to generate computational miRNA target prediction tools
[reviewed in 43], mainly based on the search for complementary sequences in the genome.
Figure 5. Chorioallantoic Membrane Metastasis Assay. (A) Schematic representation of the experiment. Cells from
the different treatment groups were transferred to the upper chorioallantoic membrane of 10-day-old chicken em‐
bryos and the number of metastatized cells into the lungs evaluated 7 days later. (B) Cells transfected with Negative
Control (NC) anti-miR or anti-miR-10a were treated with 1 μM RA or vehicle for 96 h as indicated in the figure. The
graph represents the values obtained from six parallel assays (mean ± SD). Statistical significance was analyzed by
comparing samples transfected with anti-miR-10a with those transfected with NC-anti-miR. In addition samples trans‐
fected with NC-anti-miR treated with vehicle were compared to those treated with RA.
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However, that is not an easy task, because short sequences are problematic for the algorithms
usually developed for complementarity analysis. As indicated in 2.2, the base pairing of
miRNA and mRNA in vertebrates requires only partial homology, with a preference for
contiguous pairing occurring only at the “seed” region, located at nucleotides 2-7 of the guide
strand, and this makes even more difficult to find the right target sequence in the genome.
Several authors have approached this problem from different startpoints, using mainly
complementarity analysis of the complete miRNA sequence, complementarity analysis of the
seed sequence, or adding thermodynamic stability analysis of duplex sequences or 3’UTR
sequence conservation to the complementarity analysis. Nowadays a set of miRNA target
prediction resources are available, mainly as web-based tools. However it becomes striking to
the new users of these tools how different results can be obtained when using the same
sequence with different prediction tools. In addition, prediction tools generate lists of hun‐
dreds of genes for each of the miRNAs, and the fact of having sequence diversity at the 3’UTR
by alternative polyadenylation sites could also complicate the analysis [for discussion, see 44].
To find relevant targets for miR-10a and-10b in neuroblastoma cells we choose to combine
bioinformatic prediction tools together with experimental analysis. We created a list of
potential miR-10a and -10b targets by including the common predicted genes using three
different prediction resources: miRbase targets [45], TargetScan [46] and PicTar [47]. Only
mRNAs that contained evolutionarily conserved miRNA binding sequences on their 3’UTR
were considered. This list was crossed with the dataset of an Affymetrix microarray experiment
containing the genes downregulated after 48 h RA treatment. In the resulting list, two members
of the Arginine/serine-rich splicing factors, SFRS1 (SF2/ASF) and SFRS10 (TRA2B), as well as
the nuclear receptor co-repressor NCOR2 (SMRT) were on top [30].
Figure 6. miR-10a/-10b knockdown leads to increased SFRS1 protein and mRNA levels in SH-SY5Y cells. (Left
panel) Western blot of SFRS1 protein expression after anti-miR-10a, -10b and negative control NC-anti-miR transfec‐
tion of SH-SY5Y cells followed by 1μM RA treatment. The blot was reprobed with actin beta antibodies as loading
control. (Right panel). RT-qPCR analysis of SFRS1 mRNA levels in same conditions. The graph shows expression levels
relative to that of RA untreated, NC-anti-miR transfected cells (mean ± SD of a triplicate experiment). Statistical analy‐
sis for right panel was made by comparing the values from cells transfected with anti-miR-10a or -10b to those from
cells transfected with NC-anti-miR; ns= non significative.
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4.2. Regulation of SFRS1 (SF2/ASF) by miR-10a and -10b
The regulation of SFRS1 (SF2/ASF) by miR-10a and-10b was experimentally validated at
mRNA and protein levels in HeLa and SH-SY5Y cells (Figure 6). In addition regulation by
miR-10a and -10b was shown in transfection experiments with reporter plasmids containing
SFRS1 3’UTR sequences linked to the Luciferase gene. miR-10a and -10b are new players in
the complex regulation of SFRS1 protein through a mechanism involving enhanced mRNA
cleavage. In addition, we showed how changes in miR-10a and -10b expression levels may
influence some molecular activities in which the product of SFRS1 is involved, such as
translation enhancement of certain mRNAs and alternative splicing, that could have impor‐
tance in the neural differentiation process [30] (Figure 7). We have reported that the activation
of signaling pathways by RA treatment results in rapid changes in the phosphorylation pattern
of SR proteins, including SFRS1 and subsequently, changes in alternative splicing selection
and an increase of the translation of mRNAs containing SFRS1 binding sites take place [48]. In
this context, the reduction in SFRS1 levels through miR-10a and -10b regulation could be
interpreted as the closing of the feedback regulatory loop of RA on the activities of SFRS1.
Figure 7. Experimental alteration of miR-10a and -10b levels resulted in an impairment of SFRS1 functions in the regu‐
lation of alternative splicing. Alternative splicing of tau protein exon 10 is altered by transfection of anti-miR-10a and
-10b. RT-PCR was performed on RNA extracted from anti-miR-10a, -10b or negative control (NC) anti-miR transfected
SH-SY5Y cells. tau Exon 10 flanking primers were used in RT-PCR reaction according to [49]. Quantification of the per‐
centage of exon 10 inclusion. The graph shows the average from 3 independent experiments. Statistical analysis was
made by comparing the values from cells transfected with pre-miR-10a or -10b to those from cells transfected with
NC-pre-miR.
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4.3. Regulation of NCOR2 (SMRT) by miR-10a and -10b
The regulation of NCOR2 by miR-10a and-10b was experimentally validated at mRNA and
protein levels in SK-N-BE neuroblastoma cells. Moreover, a luciferase reporter construct
containing the NCOR2 3’UTR showed a significant decrease in luciferase activity when co-
transfected with mature miR-10a, -10b or 10a/10b mimics in SK-N-BE cells. This decrease in
luciferase activity was completely abolished when the putative miR-10a and -10b target site
was mutated in its seed sequence. Knock-down of NCOR2 expression through transfection of
siRNAs to SK-N-BE cells recapitulates most of the changes induced by RA, like neurite
outgrowth, proliferative arrest, expression of neural markers, downregulation of MYCN and
expression of miR-10a [29]. NCOR2 acts as co-repressor in the regulation of many genes,
especially as co-regulator of nuclear receptor-regulated genes. Bound to the unliganded
receptor, NCOR2 maintains the promoters of nuclear receptor-regulated genes in a repressed
state, and its release from the complex with the receptor upon ligand binding allows tran‐
scriptional activation [50]. It has been reported that NCOR2 represses expression of the
jumonji-domain containing gene JMJD3, a direct retinoic-acid-receptor target that functions as
a histone H3 trimethyl K27 demethylase and which is capable of activating specific compo‐
nents of the neurogenic program [51]. Therefore, downregulation of NCOR2 by miR-10a and
-10b would potentiate the actions of RA through RARs and RXRs and could contribute to some
of the changes in gene expression associated with neural differentiation.
5. Conclusion
MicroRNAs are essential players in the process on neural differentiation of neuroblastoma
cells, and contribute to the transduction of Retinoic Acid signaling. In addition, miRNAs have
been reported to participate in the pathogenesis and progression of human neuroblastoma
tumors [2, 3], and miRNA profiles have been recently proven to be useful for classification and
prognosis [4]. Finally miRNAs open new avenues for the treatment of neuroblastoma cells,
and proof of concept experiments showing a therapeutic action of miRNA-based treatments
in animal models of neuroblastoma [52-54] and other tumors [33] have been reported.
Therefore, we have to expect in the next years an increased interest in the study of microRNAs
among the neuroblastoma researchers community.
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